MS and Demyelinating Disorders

Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath, lead investigator of the phase 3 ORATORIO-HAND trial, provided comment on the results presented at ECTRIMS 2025, highlighting ocrelizumab’s therapeutic benefit in more advanced forms of multiple sclerosis.

The pediatrician-in-chief at Johns Hopkins Children’s Center shared her reaction to receiving this year’s Bernard Sachs Award in recognition of her contributions to child neurology. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Robert Shin, MD, FAAN, professor of neurology and ophthalmology at the University of Virginia and director of the UVA MS and Clinical Neuroimmunology Center, recently shared his expertise on how multiple sclerosis (MS) affects men on the National MS Society’s Ask an MS Expert program.

Experts shared their clinical perspectives on trending topics in the treatment and management of multiple sclerosis at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 10, 2025.

Catch up on any of the neurology news headlines you may have missed in September 2025, compiled into 1 place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

In this final episode, Riley Bove, MD, considers the next phase of MS research, emphasizing the need for innovative trial designs to address sequencing, discontinuation, and subgroup-specific treatment strategies.

In this clip, a multiple sclerosis expert reflects on how ofatumumab’s role has expanded since FDA approval in 2020, from first-line use to special populations, and what this means for daily practice.

Final results from a phase 3 extension study presented at ECTRIMS 2025 demonstrated long-term efficacy and safety of ravulizumab-cwvz in patients with neuromyelitis optica spectrum disorder.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 3, 2025.

Riley Bove, MD, an associate professor of neurology at UCSF, breaks down the ARTIOS phase 3b trial results, highlighting the exceptionally low relapse rates, MRI outcomes, and safety findings in patients switching therapies.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Daniel Ontaneda, MD, PhD. [LISTEN TIME: 19 minutes]

In a phase 3 trial presented at ECTRIMS 2025, ocrelizumab demonstrated noninferior relapse control compared with fingolimod in pediatric patients with relapsing-remitting multiple sclerosis.

Primary results presented at ECTRIMS 2025 suggest that body-weight–adjusted high-dose of ocrelizumab did not further slow disease progression in patients with primary progressive multiple sclerosis.

A phase 2 study presented at ECTRIMS 2025 showed that autologous adipose-derived mesenchymal stem cell therapy was safe and effective in patients with relapsing-remitting multiple sclerosis.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the ECTRIMS Congress.

A global panel of experts revised NMOSD diagnostic criteria and updated disease classifications, distinguishing aquaporin-4 antibody–positive disease from related conditions such as MOGAD.

New research highlights the effectiveness of paramagnetic rim lesions as a key biomarker for diagnosing multiple sclerosis, enhancing diagnostic accuracy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 26, 2025.

New data reveal vidofludimus calcium shows promise in slowing disability progression in primary progressive multiple sclerosis, warranting further trials.

In a head-to-head phase 3 trial presented at ECTRIMS 2025, rituximab was noninferior to cladribine in preventing new or enlarging MRI lesions in relapsing-remitting multiple sclerosis.

In a late-breaking presentation at ECTRIMS 2025, findings showed that annual administration of rituximab was noninferior in efficacy to the 6-monthly treatment for relapsing-remitting multiple sclerosis.